GDNF and Parkinson disease: AAV2-GDNF vector represents, indeed, a rather ambitious effort, supposed to run for 5 years in patients with advanced PD, who are currently candidates to surgical DBS therapy; yet, it is not recruiting at the moment, as far as we know.